Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1998, p. 1151-1159, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Defluorinated Sparfloxacin as a New Photoproduct
Identified by Liquid Chromatography Coupled with UV Detection
and Tandem Mass Spectrometry
Michael
Engler,1
Guido
Rüsing,2
Fritz
Sörgel,2 and
Ulrike
Holzgrabe1,*
Pharmazeutisches Institut der
Universität Bonn, D-53115 Bonn,1 and
Institute for Biomedical and Pharmaceutical Research,
D-90562 Nürnberg-Heroldsberg,2 Germany
Received 24 June 1997/Returned for modification 20 December
1997/Accepted 10 February 1998
 |
ABSTRACT |
Photodegradation of sparfloxacin was observed by means of
high-pressure liquid chromatography with UV detection and liquid chromatography coupled with UV detection and tandem mass spectrometry (LC-MS/MS). Three products were detected. Comparison with an
independently synthesized derivative of sparfloxacin revealed the
structure of one product which is believed to be
8-desfluorosparfloxacin. The second product is likely to be formed by
the splitting off of a fluorine and a cyclopropyl ring. Thus,
photodefluorination of quinolone antibacterial agents is found and
proved for the first time by LC-MS/MS.
 |
INTRODUCTION |
Phototoxicity is one of the major
adverse effects of modern fluoroquinolone antibacterial agents (9,
12, 17). Two alternative models (5) have been
discussed as being the reason for phototoxicity: first, the formation
of stable toxic photoproducts leading to skin reactions
(15), and second, the formation of singlet oxygen (16), which nonspecifically injures the body. In 1975, Detzer and Huber (1) first isolated dimeric photoproducts of
nalidixic acid, a prototype quinolone antibacterial agent. Many papers
concerning the photolability of modern fluoroquinolones appeared, and
these mostly described the loss of antibiotic activity during the
course of irradiation (5-8, 13). It was hypothesized that a
high degree of fluorination may result in a low photostability and, in
line with this, in the formation of various photoproducts, which might cause adverse effects. However, little is known about the structures of
these photodegradation products.
According to the hypothesis that low stability is connected with a high
degree of fluorination, we have chosen sparfloxacin with a fluorine
substituent at the 6 and the 8 positions as a representative of the
highly fluorinated gyrase inhibitors of the newest class of drugs. The
aim of the present study is to gain more insight into the process of
photodegradation. Therefore, sparfloxacin has been irradiated in
aqueous solution, and the structures of the photoproducts that were
obtained were elucidated by means of liquid chromatography coupled with
UV detection (photodiode array detector) and tandem mass spectrometry
(LC-MS/MS). Additionally, an analog compound which is missing a
fluorine atom at position 8 has been synthesized and spectroscopically
characterized.
Part of this work was already presented as a poster at the ACS
Conference, New Orleans, La., 1996.)
 |
MATERIALS AND METHODS |
Materials.
Sparfloxacin was generously provided by
Rhône-Poulenc Rorer GmbH. Acetonitrile (Acros) was of
high-pressure liquid chromatography (HPLC) grade, and all other
reagents used were of analytical grade.
HPLC with UV detection.
HPLC was performed with a Kontron
HPLC pump 420 equipped with a Perkin-Elmer PE LC 480 Autoscan diode
array detector. The chromatographic conditions were as follows: column,
Merck LiChrosorb RP-18 (7 µm by 125 mm); loop, 20 µl; mobile phase,
acetonitrile-formic acid (0.2% in water; 50:50), isocratic; flow rate,
1 ml/min. Running of the detector in the auto-spectrum mode gave UV
spectra every second.
LC-MS/MS.
LC-MS/MS experiments were performed on a
Perkin-Elmer Sciex API III Plus biomolecular mass analyzer equipped
with an IonSpray interface. Adjustments were as follows: orifice 60 volts; split, 5/1; collision energy, 25 V for product ion scan;
collision gas thickness, 280 × 1013
atoms/cm2; nebulizer pressure, 50 lb/in2;
curtain gas flow, 0.6 liters/min. Chromatographic conditions were as
follows: loop, 200 µl; other conditions, see above.
Sample preparation and irradiation procedure.
Two milligrams
of sparfloxacin was dissolved in 100 µl of 0.1 M NaOH, and this
solution was diluted with 900 µl of water. This solution was
irradiated for 8 h in a quartz cuvette placed at a distance of 1 cm from a high-pressure mercury lamp (Philips HPK 125 W with solidex
glass filter;
= 248.2 to 578.0 nm; energy = 1.63 to 60.89 W at
different wavelengths). For observation of the degradation process, a
sample of 20 µl was taken every hour and was diluted with water to a
final concentration of 20 µg/ml for HPLC with UV detection and 40 µg/ml for LC-MS/MS.
LC-MS/MS experiments.
First, a Q1 scan was recorded, i.e.,
masses from m/z 50 to m/z 1,000 were registered
over a certain period of time (the recording is comparable to a
chromatogram). The contour plot of the Q1 scan and the extracted
spectra revealed the m/z values and retention times of the
chromatographically separated compounds. For each compound, a new run
(product ion scan of the pseudomolecular ion) was performed, giving the
fragmentation pattern of each compound.
Synthesis of the reference substance,
8-amino-1-cyclopropyl-1,4-dihydro-7-(2,6-dimethyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic
acid, compound 10.
The reference substance, compound 10, has been
synthesized by the methods described in the literature (3,
11) (Fig. 1). 1H
nuclear magnetic resonance (NMR) spectra were recorded on a Varian EM
360A spectrometer (60 MHz; tetramethylsilane was used as the
internal standard) or a Varian XL 300 spectrometer (299,956 MHz).
Melting points were determined (with a Gallenkamp melting point
apparatus) in capillary tubes and are uncorrected. Reagents were
purchased from common commercial suppliers and were used as received.
All solvents have been distilled and dried by appropriate methods.
Organic solutions were dried over anhydrous magnesium sulfate and were
concentrated with an IKA rotary evaporator at low pressure. Infrared
(IR) spectra were measured in KBr or Nujol on a Perkin-Elmer PE-298
instrument.
2,4-Dichloro-5-fluoro-3-nitrobenzoic acid, compound 1.
A
solution of 30 g (144 mmol) of 2,4-dichloro-5-fluorobenzoic acid
(3) in 360 ml of concentrated sulfuric acid was heated at
70°C. Sixty milliliters of fuming nitric acid was added dropwise over
a period of 3 h. After the addition of the acid, the reaction mixture was stirred for 2 h at 70°C and at room temperature
overnight. The mixture was poured into ice and the white precipitate
was filtered, washed with water, and dried over
P2O5 to yield 31.5 g (86%) of compound 1;
melting point, 183°C; 1H NMR (60 MHz,
methanol-d4) (ppm)
8.0 (d, 1 H, 9 Hz); IR
(cm
1) 3000, 1720, 1560, 1240, 1120.
2,4-Dichloro-5-fluoro-3-nitrobenzoyl chloride, compound 2.
A
mixture of 21 g (83 mmol) of compound 1 and 70 ml of
thionylchloride was refluxed for 1 h. The excess thionylchloride
was removed in vacuo, and the yellow residue was crystallized overnight at room temperature to give 21.8 g (91%) of compound 2, which was
used without further purification for the next step.
Ethyl (2,4-dichloro-5-fluoro-3-nitrobenzoyl)acetate, compound
4.
A total of 1.82 g (76 mmol) of magnesium was treated with
100 ml of ethanol and 1 ml of tetrachloromethane. After the reaction started, 12.16 g (76 mmol) of malonic acid diethylate, dissolved in a
mixture of 110 ml of ethanol and 300 ml of toluene, was added dropwise.
After the addition was completed the mixture was stirred at 70°C for
2 h and cooled to
10°C, and 21.8 g (76 mmol) of acid chloride, compound 2, dissolved in 110 ml of toluene was added slowly.
Stirring for 2 h at 0°C and overnight at room temperature completed the reaction. The reaction mixture was cooled to 0°C, and
under vigorous stirring, an ice-cold mixture of 200 ml water and 240 ml
of concentrated sulfuric acid was added. After extraction with toluene,
washing of the combined organic layers with saturated sodium chloride
solution, and drying of the layers over magnesium sulfate, the
evaporation of the solvent yielded 35.6 g of a mobile oil. This
oil was treated with 300 ml of water and 800 mg of
p-toluenesulfonic acid, and the mixture was refluxed for
3 h. The mixture was stirred overnight at room temperature and was
extracted with dichloromethane. The combined organic layers were dried
and evaporated to yield 23.4 g (95%) of compound 4 as a yellow
oil, which was used without further purification.
Ethyl
2-(2,4-dichloro-5-fluoro-3-nitrobenzoyl)-3-(cyclopropylamino)-acrylate,
compound 6.
A solution of 10 g (31 mmol) of compound 4, 8.8 g (60 mmol) of triethyl ortho-formate, and
10.2 g (100 mmol) of acetic anhydride was refluxed for 4 h.
The solvent was removed under reduced pressure, with the residue been
dissolved in 50 ml of ethanol. After cooling to 0°C, a solution of
1.8 g (31 mmol) of cyclopropylamine dissolved in 20 ml of ethanol
was added dropwise. The mixture was stirred for 36 h and the
precipitate was filtered and recrystallized from ethanol to give
3.36 g (28%) of a yellow powder, compound 6; melting point,
142°C; 1H NMR (300 MHz, CDCl3) (ppm) mixture
of E and Z isomers 11.01 (d, 1 H, 13.7 Hz, NH; E isomer), 9.78 (d, 1 H,
13 Hz, NH; Z isomer), 8.36 (d, 1 H, 14.5 Hz, ==CH; Z isomer), 8.27 (d,
1 H, 14.7 Hz, ==CH; E isomer), 7.17 (d, 1 H, 8.1 Hz, aromatic H; Z
isomer), 7.11 (d, 1 H, 7.9 Hz, aromatic H; E isomer), 3.99 (q, 2 H, 7 Hz, O---CH2; E isomer), 3.92 (q, 2 H, 7 Hz,
O---CH2; Z isomer), 3.01 (m, 1 H, cyclopropyl H; E isomer),
1.03 (t, 3 H, 7.1 Hz, CH3; E isomer), 0.97-0.81 (m, 4 H,
cyclopropyl CH2); IR (cm
1) 3450, 3180, 3030, 1670, 1620, 1560, 1540, 1360.
Ethyl
7-chloro-1-cyclopropyl-1,4-dihydro-6-fluoro-8-nitro-4-oxo-3-quinolinecarboxylate,
compound 7.
Ten grams (25.6 mmol) of compound 6 and 2.9 g
(25.6 mmol) of potassium tert-butoxide dissolved in 250 ml
of dioxane were refluxed for 4 h. The mixture was evaporated to
half of its volume and was poured into a mixture of 200 ml of ice
water, 40 ml of concentrated hydrochloric acid, and 75 ml of
dichloromethane. The organic layer was separated, washed with water,
dried, and evaporated. Recrystallization of the residue from ethanol
gave 7.3 g (80%) of brown crystals, compound 7; melting point,
172°C; 1H NMR (60 MHz, dimethyl sulfoxide
[DMSO]-d6 + trifluoroacetic acid) (ppm) 8.75 (s, 1 H,
==CH), 8.37 (d, 1 H, 10 Hz, aromatic H), 4.30 (q, 2 H,
O---CH2), 2.70 (m, 1 H, cyclopropyl CH), 1.35 (t, 1 H,
CH3), 1.30-1.0 (m, 4 H, cyclopropyl CH2); IR
(cm
1) 3090, 2990, 1730, 1600, 1540, 1340.
Ethyl
1-cyclopropyl-1,4-dihydro-7-(2,6-dimethyl-1-piperazinyl)-6-fluoro-8-nitro-4-oxo-3-quinolinecarboxylate,
compound 8.
A mixture of 2.8 g (7.9 mmol) of compound 7 and
3.6 g (32 mmol) of 2,6-dimethylpiperazine was refluxed in 100 ml
of acetonitrile for 2 h. After stirring overnight at room
temperature, the yellow precipitate was filtered and the mother liquid
was concentrated. Recrystallization of both residues from ethanol
yielded 3 g (88%) of compound 8; melting point, 195°C;
1H NMR (300 MHz, CDCl3) (ppm) 8.56 (s, 1 H,
==CH), 8.20 (d, 1 H, 11.3 Hz, aromatic H), 4.34 (q, 2 H, 7 Hz,
O---CH2), 3.85 (m, 1 H, cyclopropyl CH), 2.94-2.72 (m, 6 H,
piperazinyl CH and piperazinyl CH2), 1.36 (t, 3 H, 7.1 Hz,
OCH2CH3), 1.13-1.02 (m, 10 H,
piperazinyl CH3 and cyclopropyl CH2); IR
(cm
1) 3080, 2960, 1730, 1700, 1540, 1320.
1-Cyclopropyl-1,4-dihydro-7-(2,6-dimethyl-1-piperazinyl)-6-fluoro-8-nitro-4-oxo-3-quinolinecarboxylic
acid, compound 9.
A total of 1.57 g (3.6 mmol) of compound 8 was treated with a solution of 40 ml of acetic acid, 30 ml of water,
and 5 ml of concentrated sulfuric acid. The mixture was heated at
100°C for 2 h and poured onto ice. The pH was adjusted to 4 to 5 with 2 M NaOH, and the solution was extracted with chloroform. The
combined organic layers were dried and concentrated, and the yellow oil was triturated with benzine for crystallization. Subsequently, the
yellow solid was filtered and washed with benzine to give 1.46 g
(94%) of compound 9; melting point, 255 to 260°C; 1H NMR
(300 MHz, DMSO-d6 + trifluoroacetic acid) (ppm) 8.78 (s, 1 H, ==CH), 8.28 (d, 1 H, 11 Hz, aromatic H), 3.71 (m, 1 H, cyclopropyl CH), 3.28-3.15 (m, 6 H, piperazinyl CH and piperazinyl
CH2), 1.24-1.04 (m, 10 H, piperazinyl CH3 and
cyclopropyl CH2); IR (cm
1) 3020, 1720, 1600, 1550, 1320, 1260.
8-Amino-1-cyclopropyl-1,4-dihydro-7-(2,6-dimethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic
acid, compound 10.
One gram (2.5 mmol) of compound 9 was dissolved
in a solution of 30 ml of ethanol and 30 ml of acetic acid. After the
addition of 40 mg of Pd/C (10%) catalyst, the mixture was hydrogenated at room temperature and 1 bar for 24 h. After filtration and
removal of the solvent, a black oil was obtained. Treatment of the oil with benzine gave a black solid, which was recrystallized from isopropanol with activated charcoal. A second recrystallization from
isopropanol yielded 312 mg (33%) of compound 10; melting point,
259°C (decomposed); 1H NMR (300 MHz, DMSO-d6)
(ppm) 8.70 (s, 1 H, ==CH), 7.23 (d, 1 H, 12.1 Hz, aromatic H), 6.03 [s (br), 2 H, NH2], 3.77 (m, 1 H, cyclopropyl CH),
3.05-2.66 (m, 6 H, piperazinyl CH and piperazinyl CH2),
1.25-0.97 (m, 10 H, cyclopropyl CH2 and piperazinyl
CH3); IR (cm
1) 3340, 3010, 1630, 1540; UV
(nm) 242 maximum, 288, 350.
 |
RESULTS AND DISCUSSION |
Irradiation of sparfloxacin with UV light results in at least
three photoproducts (Fig. 2). As can be
detected by HPLC, the best irradiation time was found to be 4 to 8 h. After 4 h, the sparfloxacin peak decreases significantly,
whereas the other peaks increase. Irradiation times longer than 8 h did not affect the intensity of the sparfloxacin peak anymore. A
total degradation of the quinolone could not be achieved. A reason for
this might be the quenching effect in concentrated solutions described
by Morimura et al. (7). The UV spectra of all photoproducts
recorded during the HPLC run show a hypsochromic shift of 6 to 8 nm of the absorption maximum (Table 1)
indicating the loss of a weak chromophoric group, such as a fluorine
atom.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
UV data obtained from the HPLC run in acetonitrile-formic
acid (0.2%; 50:50) showing the hypsochromic shift of the
absorption maximum
|
|
In order to find similarities and changes in the MS spectra of the
photoproducts, an LC-MS/MS experiment was first performed with the
nonirradiated sparfloxacin. The fragmentation of the ion spray
ionization technique applied is different from that of electron
impact-mass spectrometry. The product ion spectrum of sparfloxacin is
displayed in Fig. 3, and the derived
fragmentation pathway is shown in Fig. 4.
The pseudomolecular ion [M+H]+ (m/z 393) can
split off of a water molecule (loss of 18 Da) or decarboxylate (loss of
44 Da). The resulting oxoquinoline ion (m/z 349) loses
different fragments of the piperazine ring. Interestingly, no
fragmentations concerning the aromatic ring system and the substituents
at N-1 are observed. The peaks m/z 98, 84, and 58 can be
explained by the presence of a pseudomolecular ion with a positive
charge on the piperazine nitrogen atom.
From the Q1 scan of the irradiated samples, a chromatogram was
obtained. The chromatogram showed three chromatographically well
separated compounds with pseudomolecular ions of 375, 335, and 405 Da.
The subsequent product ion scans of these pseudomolecular ions gave the
fragmentation patterns of all three photoproducts (Fig. 5 to
7).
As can be seen in Fig. 5, the spectra of the photoproduct
[M+H]+ with a mass of 375 Da and sparfloxacin (Fig. 3)
exhibit corresponding mass differences. The masses of all fragment ions
of the photoproduct are decreased by 18 Da. A loss of water may have
occurred upon irradiation. Since the mass difference of 18 Da is still
found in the product ion spectrum of the photoproduct
[M+H]+ with a mass of 375 Da, a conversion of the
carboxylic function is impossible. Thus, the loss of water is unlikely.
Alternatively, a photochemical replacement of one fluorine atom of
sparfloxacin with a hydrogen must be taken into account, because the UV
spectrum of the photoproduct showed a corresponding shift (Table 1).
The fact that the masses of all the fragment ions showed a difference of 18 Da further supports the hypothesis of photodefluorination (2). In order to ensure this hypothesis, the 8-desfluoro
compound (compound 10) has been synthesized, and mass and UV spectra
were recorded by using the conditions described above. As can be seen in Fig. 5 and 8, the spectra of the
photoproduct [M+H]+ with a mass of 375 Da and the
synthesized compound show nearly the same patterns of fragmentation,
indicating similar structures. The differences between the photoproduct
and compound 10 (fragment ions of m/z 274, 232, 219, 217, and 204) are due to the different positions of the amino group, which
results from a kind of "ortho effect" of the amino group
in the fragmentation pattern of compound 10 (Fig.
9). According to this observation, it
seems likely that the fluorine atom in the photoproduct takes the 6 position or, in turn, the fluorine at position 8 was split off upon
irradiation. In addition, the UV spectrum of compound 10 shows nearly
the same hypsochromic shift (
max = 288 [compound 10],
and 292 [sparfloxacin]) as the photoproduct. The finding of
defluorination of the difluorinated quinolone supports the observation
reported previously (10) that 6-monofluorinated quinolones
are found to be more photostable than 6,8-difluorinated quinolones. In
addition, the defluorination is in accordance with recently reported
results obtained with irradiated lomefloxacin and fleroxacin
(4). The defluorinated products were identified by means of
19F NMR spectroscopy.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 9.
Fragmentation pathway of the reference compound,
compound 10, under MS/MS conditions. Numbers in brackets are
m/z's.
|
|
The elucidation of the structure of the photoproducts
[M+H]+ with masses of 335 and 405 Da is more complicated
and not yet finished. The mass spectrum of the product
[M+H]+ with a mass of 335 Da (Fig. 6) exhibits the same
fragmentation pattern concerning the piperazine ring (compare with Fig.
3 for sparfloxacin) and a loss of water ([M+H]+ with a
loss of 18 Da). It is remarkable that there is no loss of
CO2 connected with the loss of water in this case, which
indicates the presence of a COOH group. Nevertheless, it seems likely
that the piperazine ring and the carboxylic group are still present. The mass difference of 58 Da between sparfloxacin ([M+H]+
with a mass of 393 Da) and the photoproduct might be explained by the
loss of two groups: first, a replacement of fluorine with a hydrogen
(18 Da), which is in agreement with the hypsochromic shift in the UV
spectrum, and second, substitution of the cyclopropyl group with a
hydrogen (40 Da) (Fig. 6). Since such a photodegradation has not yet
been described, further investigations must be performed. The
information which can be extracted from the product ion spectrum of the
photoproduct [M+H]+ with a mass of 405 Da is rather poor,
because the signals are rather weak because of the high degree of
fragmentation (Fig. 7). The base peak of m/z 291 can be
explained by the loss of a neutral piperazine ring
([M+H]+ with a mass of 405 Da
114 Da (neutral
molecule) = 291 Da). In turn, a peak for a protonated piperazine is
found at m/z 115. Thus, it is likely that the piperazine
ring is still present in this photoproduct.
Taken together, the replacement of a fluorine atom with a hydrogen atom
in the quinolone skeleton of gyrase inhibitors induced by UV light
could be confirmed by LC-MS/MS as well as with the UV spectra of two
photoproducts. The photodegradation of the piperazine ring
(levofloxacin [18], ciprofloxacin
[14]) and the carboxyl group (cinoxacin
[15]) described for other quinolones or the photodimerizations described for nalidixic acid (1) were not found in the present study.
 |
ACKNOWLEDGMENT |
We thank Armin Haag for valuable help concerning the
interpretation of the mass spectra.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Pharmazeutisches
Institut der Universität Bonn, Kreuzbergweg 26, D-53115 Bonn,
Germany. Phone: 49-228-732-845. Fax: 49-228-739-038. E-mail:
holzgrabe{at}uni-bonn.de.
 |
REFERENCES |
| 1.
|
Detzer, N., and B. Huber.
1975.
Photochemie heterocyclischer Enone I, Photolyse und Thermolyse von Nalidixinsäure.
Tetrahedron
31:1937-1941.
|
| 2.
|
Engler, M.,
U. Holzgrabe,
M. Kinzig, and F. Sörgel.
1996.
Photoproducts of sparfloxacin identified by means of LC-MS/MS, p. 173-medi.
In
Abstracts of papers of the American Chemical Society, vol. 211. , pt. 2.
|
| 3.
|
Jürgens, J.,
H. Schedletzky,
P. Heisig,
J. K. Seydel,
B. Wiedemann, and U. Holzgrabe.
1996.
Syntheses and biological activities of new N1-aryl substituted quinolone antibacterials.
Arch. Pharm. Med. Chem.
329:179-190.
|
| 4.
|
Martinez, L. J.,
G. Li, and C. F. Chignell.
1997.
Photogeneration of fluoride by the fluoroquinolone antimicrobial agents lomefloxacin and fleroxacin.
Photochem. Photobiol.
65:599-602[Medline].
|
| 5.
|
Matsumoto, M.,
K. Kojima,
H. Nagano,
S. Matsubara, and T. Yokota.
1992.
Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation.
Antimicrob. Agents Chemother.
36:1715-1719[Abstract/Free Full Text].
|
| 6.
|
Moore, D. E.,
V. J. Hemmens, and H. Yip.
1984.
Photosensitization by drugs: nalidixic and oxolinic acid.
Photochem. Photobiol.
39:57-61[Medline].
|
| 7.
|
Morimura, T.,
T. Ohno,
H. Matsukara, and Y. Nobuhara.
1995.
Photodegradation kinetics of the new fluoroquinolone derivative, orbifloxacin, in aqueous solution.
Chem. Pharm. Bull.
43:1000-1004.
|
| 8.
|
Phillips, G.,
B. E. Johnson, and J. Ferguson.
1990.
The loss of antibiotic activity of ciprofloxacin by photodegradation.
J. Antimicrob. Chemother.
26:783-789[Abstract/Free Full Text].
|
| 9.
|
Ryochi Kamide, M. D.
1993.
Drug-induced photosensitive skin diseases.
In
A. Shima, et al. (ed.), Frontiers of photobiology. Elsevier Science Publishers B.V., Amsterdam, The Netherlands.
|
| 10.
|
Sanchez, J. P.,
A. J. Bridges,
R. Bucsh,
J. M. Domagala,
R. D. Gogliotti,
S. E. Hagen,
C. L. Heifetz,
E. T. Joannides,
J. C. Sesnie,
M. A. Shapiro, and D. L. Szotek.
1992.
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risc.
J. Med. Chem.
35:361-367[Medline].
|
| 11.
|
Sanchez, J. P.,
J. M. Domagala,
S. E. Hagen,
C. L. Heifetz,
M. P. Hutt, and A. K. Trehan.
1988.
Quinolone antibacterial agents. Synthesis and structure activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids.
J. Med. Chem.
31:983-991[Medline].
|
| 12.
|
Shimada, J., and S. Hori.
1992.
Adverse effects of fluoroquinolones.
Drug Res.
38:133-143[Medline].
|
| 13.
|
Tammilehto, S.,
H. Salomies, and K. Torniainen.
1994.
Qualitative and quantitative TLC for monitoring ciprofloxacin photodegradation in aqueous solutions.
J. Planar Chromatogr.
7:368-371.
|
| 14.
|
Torniainen, K.,
J. Mattinen,
C.-P. Askolin, and S. Tammilehto.
1997.
Structure elucidation of a photodegradation product of ciprofloxacin.
J. Pharm. Biomed. Anal.
15:887-894[Medline].
|
| 15.
|
Vargas, F.,
C. Rivas, and N. Canudas.
1994.
Photosensitized lipid peroxidation by cinoxacin and its photoproducts. Involvement of a derived peroxide in its phototoxicity.
Pharmazie
49:742-745.
|
| 16.
|
Wagai, N., and K. Tawara.
1992.
Possible reasons for differences in phototoxic potential of 5 quinolone antibacterial agents: generation of toxic oxygen.
Free Radic. Res. Commun.
17:387-398[Medline].
|
| 17.
|
Wagai, N.,
M. Yoshida, and S. Takayama.
1992.
Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice.
Arzneim.-Forsch./Drug Res.
42:404-405.
|
| 18.
|
Yoshida, Y.,
E. Sato, and R. Moroi.
1993.
Photodegradation products of levofloxacin in aqueous solution.
Arzneim.-Forsch./Drug Res.
43:601-606.
|
Antimicrobial Agents and Chemotherapy, May 1998, p. 1151-1159, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Marona, H. R. N., Zuanazzi, J.A.S., Schapoval, E. E.S.
(1999). Determination of sparfloxacin and its degradation products by HPLC-PDA. J Antimicrob Chemother
44: 301-302
[Full Text]